Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy

International Journal of Cancer

Volumn 75, Issue 3, 1998, Pages 406-411

  De Jong, Marion ^a   Bakker, Willem H ^a   Breeman, Wout A P ^a   Bernard, Bert F ^a   Hofland, Leo J ^a   Visser, Theo J ^a   Srinivasan, Ananth ^b   Schmidt, Michelle ^b   Béhé, Martin ^c   Mäcke, Helmut R ^c   Krenning, Eric P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MALLINCKRODT PHARMACEUTICALS   (United States)

^c Kantonspital Basel ^*  (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; OCTREOTIDE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETATE; OCTREOTIDE PENTETIC ACID; OCTREOTIDE[3 TYROSINE PENTETIC ACID]; PENTETATE INDIUM IN 111; PENTETIC ACID DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG UPTAKE; ISOTOPE LABELING; MALE; NONHUMAN; NUCLEAR MEDICINE; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; RAT; RECEPTOR BINDING; SCINTIGRAPHY;

ANIMALS; DRUG CARRIERS; HETEROCYCLIC COMPOUNDS; HETEROCYCLIC COMPOUNDS, 1-RING; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; ISOTOPE LABELING; KIDNEY; MALE; MICE; OCTREOTIDE; PENTETIC ACID; RADIOISOTOPES; RADIOPHARMACEUTICALS; RATS; RATS, INBRED LEW; RATS, WISTAR; RECEPTORS, SOMATOSTATIN; TISSUE DISTRIBUTION; YTTRIUM RADIOISOTOPES;

EID: 0032579454     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980130)75:3<406::AID-IJC14>3.0.CO;2-6     Document Type: Article

References (22)

1. ANDERSON, C.J., SHERMAN, E.L.C., MCCARTHY, D.W., BASS, L.A., JONES, L.A., CRISTEL, ME., LANAHAN, M.V., SHEFER, R.E., KLINKOWSTEIN, R.E. and WELCH, M.J., Radiotherapy studies of Cu-64-labeled TETA-octreotide in tumor-bearing rats. J. nucl. Med., 37, 128P-129P (1996).
2. 1]octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumours: synthesis, radiolabelling and in vitro validation. Life Sci., 49, 1583-1591 (1991).
3. BAKKER, W.H., KRENNING, E.P., BREEMAN, W.A.P., KOPER, J.W., KOOIJ, P.P.M., REUBI, J.C., KLIJN, J.G., VISSER, T.J., DOCTER, R. and LAMBERTS, S.W.J., Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabelling, purification, biologic activity, and in vivo application in animals. J. nucl Med., 31, 1501-1509 (1990).
4. BEHR, T.M., SHARKEY, R.M., JUWEID, M.E., BLUMENTHAL, R.D., DUNN, R.M., GRIFFITH, G.L., BAIR, H.-J., WOLF, F.G., BECKER, W.S. and GOLDENBERG, D.M., Reduction of the renal uptake of radiolabelled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res., 55, 3825-3834 (1995).
5. 1]octreotide uptake. J. nucl. Med. (1997) (In press).
6. BRUNO, J.F. and BERELOWITZ, M., Somatostatin receptors: orphan that found family and function. Mol. cell. Neurosci., 4, 307-309 (1993).
7. 3octreotide, a promising somatostatin analogue for radionuclide therapy. Europ. J. nucl. Med., 24, 368-371 (1997).
8. 161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy. Europ. J. nucl. Med., 22, 608-616 (1995).
9. 111In-DTPA-octreotide in vivo. J. nucl. Med., 37, 1388-1392 (1996).
10. DUNCAN, J.R., STEPHENSON, M.T., WU, H.P. and ANDERSON, C.J., Indium111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal and hepatocyte lysosomes. Cancer Res., 57, 659-671 (1997).
11. FRIEDMAN, M., Formation, nutritional value, and safety of D-amino acids. In: M. Friedman (ed.), Nutritional and toxicological consequences of food processing, pp. 447-481, Plenum, New York (1991).
12. GULLINO, P., WINITZ, M., BIRNBAUM, S.M., CLYDE OTEY, M., CORNFIELD, J. and GREENSTEIN, J.P., The toxicity of individual essential amino acids and their diastereomers in rats and the effect on blood sugar levels. Arch. Biochem. Biophys., 58, 253-255 (1995).
13. HAMMOND, P.J., WADE, A.F., GWILLIAM, M.E., PETERS, A.M., MYERS, M.J., GILBEY, S.G., BLOOM, S.R. and CALAM, J., Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue. Brit. J. Cancer, 67, 1437-1439 (1993).
14. 3]octreotide, by mouse and human pituitary tumour cells. Endocrinology, 136, 3698-3706 (1995).
15. HOFLAND, L.J., VAN KOETSVELD, P.M., WOUTERS, N., WAAIJERS, M., REUBI, J.C. and LAMBERTS, S.W.J., Dissociation of antiproliferative and antihormonal effect of the somatostatin analogue octreotide on 7315b pituitary tumor cells. Endocrinology, 131, 571-577 (1992).
16. JOWSEY, J., ROWLAND, R.E. and MARSHALL, J.H., The deposition of the rare earths in bone. Radiat. Res., 8, 490-501 (1958).
17. KRENNING, E.P., KOOIJ, P.P.M., PAUWELS, S., BREEMAN, W.A.P., POSTEMA, P.T.E., DE HERDER, W.W., VALKEMA, R. and KWEKKEBOOM, D.J., Somatostatin receptor scintigraphy and radionuclide therapy. Digestion, 57, 57-61 (1996).
18. 3-octreotide: the Rotterdam experience with more than 1000 patients. Europ. J. nucl. Med., 20, 716-731 (1993).
19. PIMM, M.V. and GRIBBEN, S.J., Prevention of renal tubule reabsorption of radiometal (indium-111) labelled Fab fragment of a monoclonal antibody in mice by systemic administration of lysine. Europ. J. nucl. Med., 21, 663-665 (1994).
20. ROWLINSON, G., SNOOK, D., STEWART, S. and EPENETOS, A.A., Intravenous EDTA to reduce bone uptake of Y-90 following Y-90 labeled antibody administration, Brit. J. Cancer, 59, 322 (1989).
21. STOLZ, B., SMITH-JONES, P.M., ALBERT, R., TOLCSVAI, L., BRINER, U., RUSER, B., MÄCKE, H., WECKBECKER, G. and BRUNS, C., Somatostatin analogues for somatostatin-receptor-mediated radiotherapy of cancer. Digestion, 57, 17-21 (1996).
22. YAMADA, Y., KAGIMOTO, S., KUBOTA, A., YASUDA, K., MASUDA, K., SOMEYA, Y., IHARA, Y., LI, Q., IMURA, H., SEINO, S. and SEINO, Y., Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. Biochem. biophys. Res. Comm., 195, 844-852 (1993).